A case of methotrexate resistant gestational trophoblastic neoplasia

Gestational trophoblastic neoplasia (GTN) is a subset of gestational trophoblastic disease (GTD) which has a propensity to invade locally and metastasize. Patients with low risk GTN generally respond well to single agent chemotherapy (methotrexate (MTX) or actinomycin-D (ACT-D). However, high risk cases may develop resistance or may not respond to this first-line chemotherapy and are unlikely to be cured with single-agent therapy. Therefore, combination chemotherapy is used for treatment of these cases. Here we present a 25 years old P2 L2 A1 lady, who was initially treated at a peripheral hospital with multiple doses of Injection methotrexate with a working diagnosis of persistent trophoblastic disease. She didn’t respond to this treatment and reported to our centre for further management. On evaluation she was found to be a case of high risk GTN (invasive mole) (I:8) for which she was put on combination chemotherapy in the form of Etoposide-Methotrexate-Actinomycin-Cyclophosphamide-Oncovin (EMA-CO) regime. She responded to this treatment and is presently asymptomatic and is under regular follow up.

[1]  Sanjay Singh,et al.  A case of methotrexate resistant gestational trophoblastic neoplasia , 2018, International Journal of Reproduction, Contraception, Obstetrics and Gynecology.

[2]  P. Kushtagi,et al.  Variation in Prevalence of Gestational Trophoblastic Disease in India , 2016, Indian Journal of Gynecologic Oncology.

[3]  S. Aziz,et al.  Management of gestational trophoblastic neoplasia , 2015 .

[4]  W. Kang,et al.  Prediction of persistent gestational trophobalstic neoplasia: the role of hCG level and ratio in 2 weeks after evacuation of complete mole. , 2012, Gynecologic oncology.

[5]  R. Berkowitz,et al.  Current management of gestational trophoblastic neoplasia. , 2012, Hematology/oncology clinics of North America.

[6]  T. Lawrie,et al.  Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. , 2012, The Cochrane database of systematic reviews.

[7]  J. Lurain Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. , 2010, American journal of obstetrics and gynecology.

[8]  R. Hanna,et al.  The role of surgery and radiation therapy in the management of gestational trophoblastic disease. , 2010, The oncologist.

[9]  Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[10]  R. Berkowitz,et al.  Current management of gestational trophoblastic diseases. , 2009, Gynecologic oncology.

[11]  R. Berkowitz,et al.  Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. , 2008, The Journal of reproductive medicine.

[12]  R. Berkowitz,et al.  The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. , 2005, Gynecologic oncology.

[13]  N. Sebire,et al.  Overdiagnosis of Complete and Partial Hydatidiform Mole in Tubal Ectopic Pregnancies , 2005, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[14]  R. Mclellan,et al.  Gestational trophoblastic disease. , 2001, Obstetrics and gynecology clinics of North America.